Immunix® Precision Therapeutics Platform
Turning biological data into real-time clinical insight
One Platform. Two Critical Functions.
Immunix® is a modular, cloud-based platform that integrates directly into hospital EHRs, developed to:
Conduct the research that identifies and validates precision therapeutics.
Deliver AI-biomarker results in real time, directly within clinical workflows.
Keeping Pace with Fast-Moving Biology
Built to Power Efficient Clinical Trials
Because Immunix is directly integrated with the EHR system, it quickly screens and recruits patients for clinical trials, identifies usable remnant samples, and gathers study data.
That speed matters. Critical illness moves fast, and a patient’s biology can shift within hours. Immunix identifies and enrolls eligible patients before narrow treatment windows close, and keeps gathering data throughout the encounter as that biology evolves. The result? Faster patient enrollment, more representative patient populations, and clinical trials that focus on precision using individual patient biology.
Precision at the Point of Care
Real-time Results, Right in the Clinical Workflow
Immunix is HIPAA-compliant, cloud-based software that integrates directly into the EHR, so clinicians can order AI-biomarkers the same way they order any other test. No new devices are needed. Using a combination of HL7 V2 and FHIR APIs, it pulls relevant clinical data, prompts for anything additional needed, and returns results directly in the patient’s chart in real time.
Helps clinicians act faster
Supports better outcomes
Strengthens care quality and financial performance metrics
A Living Map of Immune-Driven Conditions
Integrating Diagnostics and Therapeutics
With every trial, with every study, our biobank grows, which means the Immunix platform is a constantly evolving map of biological insights, continuously learning to determine how each patient will respond to particular treatment. This map enables us to connect diagnosis directly to treatment, matching each patient’s biology to the intervention most likely to work for them.
The First-Ever FDA-Authorized AI-Biomarker for Sepsis
Sepsis ImmunoScore® is the first AI-Biomarker to deploy on the Immunix platform. De Novo authorized by the FDA, it provides clinicians with an objective assessment of patients at elevated risk for sepsis or progression within 24 hours, based on 22 biological markers.
Clinical Trial Recruitment and Management
Immunix screens for eligibility, identifies usable remnant samples, and gathers study data, helping trials enroll faster and reach more representative patient populations, without adding work for hospital staff.
Proprietary Biobank and Dataset
NOSIS™ is the biological engine behind Immunix — one of the largest acute illness biobanks in existence, continuously growing with every patient encounter.